LAS VEGAS, Oct. 31, 2002 (PRIMEZONE) -- Coyote Ventures Corp. (OTCBB:CYTV) (the "Company") announces today that the Company has appointed Peter Whitehead to its Board of Directors and to the position of Vice President of Corporate Development. Mr. Whitehead brings several years of experience in cancer research and biophysics with the British Columbia Cancer Association (BCCA) combined with expertise in biomedical product development in the field of cardiology. As well, Mr. Whitehead has been published in Circulation, the world's largest peer-review cardiology journal, and invented and patented cardiac transplant rejection monitors which underwent clinical trials at the Cleveland Clinic, Stanford University, Temple University and St. Paul's Hospital, Vancouver.
Mr. Scott Houghton, Coyote President and CEO, said, "We are very pleased to have Mr. Whitehead join our Board. Mr. Whitehead's extensive experience in leading-edge cancer research and biomedical product development is ideal for our growing firm. Mr. Whitehead has been instrumental in the development of August Research's two latest products used to improve cervical and oral cancer detection. Our medical and scientific advisors as well as the Board of Directors and management team are all very excited to have him join our team."
Mr. Whitehead said, "I believe the potential of these products will strongly impact the localization and effective treatment of cancer at earlier stages of growth. Optically-based fluorescence imaging is likely to become increasingly important and more broadly applied in conjunction with research advances that are identifying molecular markers of different types of cancer."
Coyote Ventures Corp. and its subsidiaries, are engaged in the research, development and commercialization of medical imaging technologies, which aids in the detection and localization of cancer.
Public Company Disclosure
This document may contain certain forward-looking statements regarding Coyote Ventures Inc. including statements about its operations, prospects and expectations about future financial results, including, but not limited to, future revenues and earnings. The words "estimate," "possible," "expects," "anticipates," "believes," "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. These forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially and are subject to change at any time. The Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including those risks and uncertainties detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2001 filed with the SEC as well as subsequent forms 8-Ks, 10-Qs, 14-C and S-8 registrations.